ArticleEMBO molecular medicine2023
Microbial metabolites in chronic heart failure and its common comorbidities.
Article in EMBO molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Microbial metabolites associated in stool and left ventricle of heart failure patients revealed by meta-analysis.Scientific reports · 2025Pooled it
- Circulating imidazole propionate and coronary heart disease risk: interplay between histidine intake, fiber, and gut microbiome.BMC medicine · 2026Article
- Multi-kingdom profiling reveals altered gut phage-bacteria-metabolite interactions in MASLD.Nature communications · 2026Article
- metadeconfoundR: Covariate analysis of high-dimensional cross-sectional omics data.Bioinformatics advances · 2026Article
- Exploring the intricate link between gut microbiota dysbiosis and the aging process: implications for age-related diseases.Gut pathogens · 2025Review
- Identification and prognosis of low office and ambulatory blood pressure in patients with heart failure.Annals of medicine · 2025Article
- Defining histamine H2 receptor antagonist response in critically ill patients with heart failure: a machine learning cluster analysis.International journal of clinical pharmacy · 2025Article
- Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes.Nature medicine · 2025Article
- Comparative serum imidazole propionate profiling in colorectal adenoma and cancer by UPLC-MS/MS.BMC gastroenterology · 2025Article
- Gut-Heart Axis: The Role of Gut Microbiota and Metabolites in Heart Failure.Circulation research · 2025Review
- Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice.Nature communications · 2025Article
- Gut microbiota-derived imidazole propionate: an emerging target for the prevention and treatment of cardiometabolic diseases.Frontiers in endocrinology · 2025Review
- Diabetes in China: epidemiology, pathophysiology and multi-omics.Nature metabolism · 2025 · on this mapReview
- Improving Nutritional Status in Chronic Heart Failure Patients: Effectiveness of a Transtheoretical Model-Based Stepwise Nutritional Management Program.Risk management and healthcare policy · 2025Article
- Gut microbiota-generated metabolites: missing puzzles to hosts' health, diseases, and aging.BMB reports · 2024Review
- Gut Microbiota Alterations and Circulating Imidazole Propionate Levels Are Associated With Obstructive Coronary Artery Disease in People With HIV.The Journal of infectious diseases · 2024Article
- Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights.Frontiers of medicine · 2024Review
- Imidazole propionate in type 2 diabetes mellitus and cardiovascular diseases: a mini review.Frontiers in immunology · 2024Review
- Branched-chain amino acids deficiency promotes diabetic cardiomyopathy by activating autophagy of cardiac fibroblasts.Theranostics · 2024Article
- Prognostic value of serum IGF-1, Gal-3, and PTX-3 levels in elderly patients with chronic heart failure.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify microbial signatures that contribute to the shared etiologies between chronic heart failure (CHF), type 2 diabetes, and chronic kidney disease. The serum levels of 151 microbial metabolites were measured in 260 individuals from the Risk Evaluation and Management of heart failure cohort, and it was found that those metabolites varied by an order of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.